Treatment of Aggressive Non-Hodgkin??s Lymphoma with Chemotherapy in Combination with Filgrastim

Schriber, Jeff

doi:10.2165/00003495-200262001-00003

Cited by 5 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 is currently used as a therapy for leukemia (1)(2)(3)(4) and severe genetic disorders such as Wiskott-Aldrich syndrome (5,6). In addition, it demonstrates some potential in the treatment of some aggressive autoimmune diseases (7,8).…”

Section: B One Marrow Transplantation (Bmt)mentioning

confidence: 99%

Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology

Lang

Recher

Navarini

et al. 2005

The Journal of Immunology

View full text Add to dashboard Cite

Bone marrow transplantation (BMT) is commonly used in the treatment of leukemia, however its therapeutic application is partly limited by the high incidence of associated opportunistic infections. We modeled this clinical situation by infecting mice that underwent BMT with lymphocytic choriomeningitis virus (LCMV) and investigated the potential of immunotherapeutic strategies to counter such infections. All mice that received BMT survived LCMV infection and developed a virus carrier status. Immunotherapy by adoptive transfer of naive splenocytes protected against low (200 PFU), but not high (2 × 106 PFU), doses of LCMV. Attempts to control infection of high viral titers using strongly elevated frequencies of activated LCMV-specific T cells failed to control virus and resulted in immunopathology and death. In contrast, virus neutralizing Abs combined with naive splenocytes were able to efficiently control high-dose LCMV infection without associated side effects. Thus, cell transfer combined with neutralizing Abs represented the most effective means of controlling BMT-associated opportunistic viral infection in our in vivo model. These data underscore the in vivo efficacy and immunopathological “safety” of neutralizing antibodies.

show abstract

Section: B One Marrow Transplantation (Bmt)mentioning

confidence: 99%

Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology

Lang

Recher

Navarini

et al. 2005

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

Current Awareness in Hematological Oncology

2003

Hematological Oncology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of hematological oncology. Each bibliography is divided into 14 sections: 1 Books, Reviews & Symposia; 2 General; Leukemias: 3 Lymphoblastic; 4 Myeloid & Myelodysplastic Syndromes; 5 Chronic; 6 Others; Lymphomas: 7 Hodgkin's; 8 Non‐Hodgkin's; 9 Plasmacytomas/Multiple Myelomas; 10 Others; 11 Bone Marrow Transplantation; 12 Cytokines; 13 Diagnosis; 14 Cytogenetics. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

The Interplay Between C-Myc Oncogene Expression and Circulating Vascular Endothelial Growth Factor (sVEGF), Its Antagonist Receptor, Soluble Flt-1 in Diffuse Large B Cell Lymphoma (DLBCL): Relationship to Patient Outcome

Aref

Mabed

Zalata

et al. 2004

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

Treatment of Aggressive Non-Hodgkin??s Lymphoma with Chemotherapy in Combination with Filgrastim

Cited by 5 publications

References 60 publications

Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology

Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology

Current Awareness in Hematological Oncology

The Interplay Between C-Myc Oncogene Expression and Circulating Vascular Endothelial Growth Factor (sVEGF), Its Antagonist Receptor, Soluble Flt-1 in Diffuse Large B Cell Lymphoma (DLBCL): Relationship to Patient Outcome

Contact Info

Product

Resources

About